The deal highlights Medtronic’s commitment to minimally invasive solutions and high-growth markets.
Medtronic has acquired Fortimedix Surgical, a Dutch medtech company specializing in articulating instruments for endoscopic and minimally invasive procedures. These flexible tools enable precision navigation through the body, reducing trauma and recovery times.
The acquisition complements Medtronic’s efforts to enhance its Hugo soft tissue robot, expected to seek U.S. approval for urology procedures in early 2025.
Fortimedix’s Contributions to Minimally Invasive Surgery
Fortimedix has shifted its focus from its Symphonx single-port surgery system to versatile instruments for non-invasive procedures. The company’s technology allows surgeons to access treatment areas through natural openings like the mouth, lowering complication risks and recovery times.
“Traditional surgery requires multiple entry points, causing trauma. Our instruments enter via natural pathways, minimizing risks,” said Wout Bijker, Fortimedix CEO.
Medtronic’s Strategic Growth Vision
The acquisition aligns with Medtronic CEO Geoff Martha’s focus on “tuck-in acquisitions” to strengthen key areas like surgical robotics. Integrating Fortimedix’s tools is expected to enhance Hugo’s functionality and improve Medtronic’s competitive edge.
By advancing less invasive and more efficient surgical solutions, Medtronic reaffirms its commitment to innovation and improved patient outcomes.
Follow MEDWIRE.AI for the latest updates on MedTech advancements and strategic healthcare acquisitions.
